ANTISENSE THERAPEUTICS IN HAEMATOLOGICAL MALIGNANCIES
- 1 July 1994
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 87 (3), 447-452
- https://doi.org/10.1111/j.1365-2141.1994.tb08296.x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- BCR-ABL antisense purging in chronic myeloid leukaemiaThe Lancet, 1993
- Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.Journal of Clinical Investigation, 1993
- Oligonucleotide degradation contributes to resistance to antisense compoundsAnti-Cancer Drugs, 1993
- Antisense oligomers in chronic myeloid leukaemiaThe Lancet, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Use of Cell-Free Retroviral Vector Preparations for Transduction of Cells from the Marrow of Chronic Phase and Blast Crisis Chronic Myelogenous Leukemia Patients and from Normal IndividualsHuman Gene Therapy, 1992
- Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides.The Journal of Experimental Medicine, 1991
- Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis.Journal of Clinical Investigation, 1990
- A c- myb Antisense Oligodeoxynucleotide Inhibits Normal Human Hematopoiesis in VitroScience, 1988
- Amplification of the c- myb Oncogene in a Case of Human Acute Myelogenous LeukemiaScience, 1984